Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Gut Microbes: A Target in Primary Biliary Cholangitis?
Gut; ePub Feb 17; Tang, Wei, et al
Targeting the gut microbiota may offer a new therapeutic option for patients with primary biliary cholangitis (PBC), according to a recent study. The study found intestinal dysbiosis was more common in patients with PBC, when compared to healthy controls. Among the specific findings:
- 4 genera of microbes were less common in PBC patients.
- 8 genera were more prevalent in PBC patients.
- The diversity of microbes was diminished within the guts of individual patients with cholangitis.
- Faecalibacterium, which was common among controls, was further decreased in gp210-positive patients, when compared to gp210-negative patients.
- Bacterial invasion of epithelial cells among patients with BPC was strongly correlated with the presence of Enterobacteriaceae.
Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. [Published online ahead of print February 17, 2017]. Gut. doi:10.1136/gutjnl-2016-313332.
This Week's Must Reads
Must Reads in PBC (Primary Biliary Cholangitis)
Age, Sex, & IBD Linked to Sclerosing Cholangitis Outcomes, Gastroenterology; ePub 2017 Mar 6; Weismuller, et al
Patients with PBC More Likely to Die Waiting for Transplants, Transpl Int; 2017 May; Singal, et al
European Guidelines for Primary Biliary Cholangitis, J Hepatol; ePub 2017 Apr 17; EASL
Autoreactive Antibodies Linked to Xenobiotics in PBC, Hepatology; ePub 2017 May 3; Tanaka, et al
Can PBC Diagnostic Tests Help Track Disease Progress?, Immunol Res; 2017 Feb; Alfano, et al